Azur Pharma has entered into an agreement with BioSante Pharmaceuticals to acquire US rights to Elestrin for $3.3 million.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.